OBJECTIVE:To investigate the application situation and tendency of antihypertensive drugs in our hospital. METHODS: By a retrospective study,a total of 952 prescriptions of outpatients with hypertension were sampled from our hospital from Nov. 18 to Dec. 17 in 2007 for statistical analysis regarding the utilization of antihypertensive drugs,the treatment regimens,sales amount,DDDs and DDC,etc. RESULTS: The antihypertensive drugs were mainly used in single or two kinds concomitantly. Calcium-channel blocker (CCB) and angiotensin receptor Ⅱ binders(ARB) took the lead,accounting for 30.67% and 28.45%,respectively. Leading the first three places on the list of DDDs were Telmisartan,Amlodipine and Benidipine,and leading the first three places on the list of sales amount were Telmisartan,Valsartan and Amlodipine. CONCLUSION:The use of antihypertensive drugs in our hospital conforms to China Guidelines on Prevention and Management of Hypertension and the drug use criteria recommended by WHO.

Non-surgical therapy is important to liver cancer treatment. Actinotheraphy and chemotherapy, because of their less specific for cancer tissue and serious side effect, badly affect the patients' life qualities, sometimes even endanger the patients lives. Hepatocellular carcinoma specific antibodies have been the focus of liver cancer biotherapy. After 20 years of study since 1975, it has been demonstrated that antibodies derived from mouse could not efficiently stimulate the functions of human reactor, but could induce human anti-mouse antibody responses which could bring about serious side effects. The application of DNA recombination technique provides a good method for resolving the immune selection problem. The techniques of humanoriginated antibodies and phage displaying will lead to development of innovative strategies to manage liver cancer. In our country, the antibody products aimed at cancer all originated from mouse while the study of human antibodies is still at its primary stage. Non-human antibodies has been forbidden in clinical trails by FDA in America since 2001. It can be speculated that human antibody products will domminate the future market rapidly.

Acute lung injury ( ALI) is a type of pulmonary excessive inflammation with high morbidity and mortality.It can be induced by multiple causes.There are currently no successful therapeutic or preventive measures because the patho-genesis of ALI has not been completely clarified.Many studies have shown that the activation of complement 5a (C5a) and its receptors is necessary in the process of ALI.Drug development targeting on C5a and its receptors may bring new hope to the treatment of ALI.In this article, the experimental evidence and possible mechanisms are summarized to reveal the rela-tionship between C5a and ALI.

Researchers have long focused on the adaptive behavior,quality of life,dual diagnosis,personality motivation and families of persons with mental retardation,but failed to address virtue and well-being.Unlike even a decade ago,we can now well afford to turn the emphasis to the positive,internal states of those with mental retardation.Using the breakthroughs in positive psychology,these findings such as positive trait or positive experience,can proposes a new research agenda to mental retardation.Mental retardation can play an important role in positive psychology,but it needs the research and data support in future.

Objective:To develop an HPLC-MS/MS method for the determination of rosuvastatin in plasma and study the relative bioavailability and bioequivalence of the capsules and tablets in Chinese healthy volunteers. Methods: A single oral dose (20 mg of the test or reference preparation) was given to 24 male healthy volunteers in a randomized crossover study. The plasma concentration of rosuvastatin was determined by HPLC-MS/MS. The pharmacokinetic parameters were calculated and the bioavailability and bioequiva-lence of the two preparations were evaluated by DAS 3. 0 software. Results:After a single dose, the pharmacokinetic parameters of ro-suvastatin capsules and tablets were as follows:Tmax was (3. 56 ± 1. 68) h and (3. 63 ± 1. 56) h, Cmax was (21. 17 ± 13. 74) ng· ml-1 and (26.33 ±23.22) ng·ml-1, t1/2 was (10.68 ±5.50) h and (9.04 ±6.00) h, AUC0-t was (219.31 ±146.09) ng·h· ml-1 and (252. 43 ± 194. 96) ng·h·ml-1 , AUC0-∞ was (225. 32 ± 146. 76) ng·h·ml-1 and (257. 24 ± 194. 61) ng·h·ml-1 , respectively. The 90% confidential interval of AUC0-t, AUC0-∞ and Cmax was 81. 1%-106% , 81. 8%-105. 4% and 77. 9%-104. 5%, respectively. The mean relative bioavailability of the test preparation(the capsules) to the reference preparation(the tablets) was (100. 7 ± 54. 1)%. Conclusion:The test and reference preparations are bioequivalent.

OBJECTIVE:To discuss the way for clinical pharmacists to carry out pharmaceutical care.METHODS:We summarized the content,method and experiences of carrying out pharmaceutical care based on our clinical practice in Cardiology department.RESULTS & CONCLUSION:To provide all-round high quality pharmaceutical care for patients,clinical pharmacists should improve their own qualities by continuous learning knowledge and theories related to their own profession as well as improving their practical skills.

OBJECTIVE:A HPLC method has been developed to determine the concentration of isoniazid in plasma.METH_ODS:The Eclipse XDB-C18 column was used as fix phase and acetonitrile-0.05mol/L ammonium dihydrogen phosphate as mo_bile phase,detection wavelength was 280nm.The plasma sample was injected directly for determination after being deproteinized with 10% trichloroacetic acid and reacted with cinnamaldehyde and abstracted with ether.RESULTS:Good linear relationship was shown from 0.10 to 12.0?g/ml and the averge recovery of isoniazid was 95%～105%.CONCLUSION:The method is rapid,sensitive and is rarely interfered so it can be used in study of pharmacokinetics of isoniazid.

OBJECTIVE:To study the pharmacokinetics and relative bioavailability of compound rifampicin tablets MET_HODS:Plasma levels of rifampicin(RFP),isoniazid(INH)and pyrazinamid(PZA) at different time were determined by HPLC methods,then we drew the time-concentration curves and got the pharmacokinetic parameters and relative bioavailability of test-tablets based on the curves RESULTS:The main pharmacokinetic parameters of RFP,INH and PZA in test-tablets were:Tmax,(1 69?0 60)h,(0 94?0 57)h and(2 36?1 10)h;Cmax,(9 86?2 09)?g/ml,(5 36?1 77)?g/ml and (16 20?4 85)?g/ml;T1/2,(3 43?0 72)h,(2 98?0 75)h and(9 26?1 58)h;AUC0～t,(59 34?13 17)?g/(ml?h),(21 87?14 29)?g/(ml?h) and(212 97?71 52)?g/(ml?h) respectively The main pharmacokinetic parameters of RFP,INH and PZA in control tablets were Tmax,(1 83?0 66)h,(0 86?0 38)h and (2 08?0 97)h;Cmax,(9 98?1 63)?g/ml,(5 60?2 01)?g/ml and (17 79?4 57)?g/ml;T1/2,(3 97?1 58)h,(3 15?0 88)h and (9 36?1 85)h;AUC0～t,(62 46?14 02)?g?h/ml,(21 39?14 53)?g/(ml?h) and (227 09?70 91)?g/(ml?h) respectively The relative bioavailability of test-tablets were (98 47?15 00)%,(103 76?15 80)% and (94 38?12 07)% CONCLUSION:The results of two one-sided tests and rank sum test showed that two formulae were statistically bioequivalent

OBJECTIVE:To evaluate the bioequivalence of two preparations of gemfibrozil.METHODS:A single oral dose of gemfibrozil enteric capsule(test preparation)and capsule(reference preparation)was given to20volunteers in an open ran?domized crossover way to study the pharmacokinetics and relative bioavailability.The plasma gemfibrozil concentrations were determined by HPLC method.RESULTS:The pharmacokinetic parameters of test and reference preparations were as follows:T max ,(2.4?0.6)h and(2.3?0.7)h;C max ,(21.8?7.3)?g/ml and(23.7?5.9)?g/ml;T 1/2 ,(2.0?0.4)h and(2.0?0.5)h;AUC 0～12 ,(68.1?13.7)(?g?h)/ml and(68.9?17.4)(?g?h)/ml;AUC 0～∞ (69.7?13.9)(?g?h)/ml and(70.6?17.8)(?g?h)/ml respectively.The relative bioavailability of test preparation was(100.8?15.0)%.The result of statistical analysis on above parameters showed that there was no significant difference between two preparations.CONCLUSION:The two prepa?rations were bioequivalent.

Objective To investigate the biological properties of human amniotic mesenchymal stem cells (hAMSCs) which were preconditioned with phosphodiesterase-5 inhibitor (Vardenfil). Methods hAMSCs were in vitro isolated and cultured, hAMSCs were pre-treated with vardenfil in final concentration of 10 μmol/L. The morphology of Vard-hAMSCs was observed, and the immunological characteristics, proliferative capacity, and ability of anti-oxidative damage of hAMSCs and Vard-hAMSCs were analyzed by flow cytometry. Double labeling immunofluorescent staining was used to count the differences of differential potential between neural cells of hAMSCs and Vard-hAMSCs. Results (1)Flow cytometry revealed that both hAMSCs and Vard-hAMSCs positively expressed CD90、CD105 and CD73, and negatively expressed CD34、CD45、CD11b and HLA-DR. The SPF and PI in Vard-hAMSCs group were (0.57 ± 0.40)% and (2.20 ± 1.60)% respectively, there was no statistical significance compared with hAMSCs group; (2)After 4 hours treated by H2O2, the apoptosis rate in Vard-hAMSCs group were (7.67 ± 0.82)%,which were markedly lower than that in the hAMSCs group and specific blocker group; (3)Under the same induction condition, positive rates of MAP-2 and GFAP in Vard-hAMSCs group were (49.8 ± 6.42)%and (55.2 ± 6.10)% respectively detected by double labeling immunofluorescent staining, which were significantly higher than the control group. Conclusion The strategy that hAMSCs are treated with vandenfil can enrich the ability of anti-oxidative damage and the differential potential for neural cells in a certain time, and the morphology, immunological characteristics, proliferative capacity of Vard-hAMSCs have no significant change. It suggests that pre-treatment with vandenfil may provide a optimized experimental strategey for hAMSCs which were used to treat nervous system disease.